Mdma molecule:

Image from PubChem

Mdma Clinical Trials


Study of the interaction of haloperidol and THC (cannabis) in healthy volunteers.


To see complete record on www.trialregister.nl, please visit this link

Id: NTR1731

Organisation Name: See scientific contact Zie contact wetenschappelijk

Overal Status: Stopped, trial finished

Start Date: 2007-12-13

Lead Sponsor: See scientific contact Zie contact wetenschappelijk

Brief Summary: Background:

In this study the hypothesis that haloperidol would lead to an amelioration of delta-9-tetrahydrocannabinol (THC)-induced ‘psychotomimetic’ effects was investigated.


Methods:

In a double-blind, placebo-controlled, partial 3-way crossover ascending dose study the effects of THC, haloperidol and their combination were investigated in 35 healthy male mild cannabis users, measuring Positive and Negative Syndrome Scale (PANSS), Visual Analogue Scales (VAS) for alertness, mood, calmness and psychedelic effects, saccadic and smooth pursuit eye measurements, EEG, body sway, Stroop test, Visual and Verbal Learning Task, hormone levels and pharmacokinetics.


Results:

Compared to placebo, THC significantly decreased smooth pursuit, VAS alertness, Stroop test performance, immediate and delayed word recall and prolactin concentrations and significantly increased positive and general PANSS score, VAS feeling high, body sway and EEG alpha. Haloperidol reversed the THC-induced positive PANSS increase to levels observed with haloperidol alone. However, haloperidol did not have any effects on the ‘high’ feelings induced by THC.
Compared to placebo, haloperidol significantly decreased saccadic peak velocity, smooth pursuit, VAS mood and immediate and delayed word recall and significantly increased body sway, EEG theta and prolactin levels.


Conclusions:

THC-induced increases in positive PANSS but not in VAS feeling high were reversed by haloperidol. This indicates that psychotic-like effects induced by THC are mediated by dopaminergic systems, but that other systems are involved in ‘feeling high’. In addition, the clear reductions of psychotic-like symptoms by a clinically relevant dose of haloperidol suggest that THC administration may be a useful pharmacological cannabinoid model for psychotic effects in healthy volunteers.

Country: Netherlands



Total execution time in seconds: 0.082734107971191